National security spokesperson to continue pressing for a temporary ceasefire that Washington wants to last for at least six weeks
mena2 hours ago
G42 Healthcare, a subsidiary of Abu Dhabi-based technology company Group 42 (G42), announced today it has signed a Memorandum of Understanding with NanoScent, an Israeli company specialised in scent reading technologies, to explore collaborations in the development, validation, distribution and manufacturing of Scent Check - a revolutionary solution capable of detecting suspected cases of Covid-19 from a sample of exhaled nasal air.
Also read: UAE, Israel companies sign 'strategic agreement' to fight Covid
The Scent Check device detects a combination of volatile organic compounds, or "VOC Signature", from exhaled nasal air that is derived from the host response to the SARS-CoV-2 infection. The air sample is seamlessly captured through an "Air trap", a small bag fitted with a straw in which the tested subject needs to blow nasal air. A machine learning based model is then used to analyze, diagnose and label the VOC Signature and provide the result of the test in 30 to 60 seconds.
The non-invasiveness and the rapidity of results give Scent Check the potential to transform the diagnostics industry globally. The solution enables testing in both large and small settings, without the need for complex infrastructure and cost-efficiently.
Executives from both companies took part in a signing ceremony held via video conference between the UAE and Israel. During the event, they discussed ways of leveraging respective expertise and technologies to expedite the launch of the solution in a phase in which, given the absence of a vaccine, the most effective way to break the transmission patterns of COVID-19 is mass-testing.
NanoScent releases a short training video for all the sites to gather the important data about the #COVID19 . With this process we are getting closer to defining what is the "#coronavirus scent". Important step towards a holistic solution for a mass screening. pic.twitter.com/NEx0yZXqMRAshish Koshy, CEO of G42 Healthcare, commented: "At G42 Healthcare we are at the forefront of the battle against Covid-19 and committed to developing impactful innovative programs and solutions to improve and safeguard public health. Through this collaboration with NanoScent, we will be adding another powerful solution to our comprehensive diagnostics portfolio, which already includes PCR and LamPORE testing. This partnership also reaffirms the need to tackle the COVID-19 pandemic through a joint global effort in which best-in-breed organizations share their expertise and technologies for the benefit of society.
- NanoScent (@nanoscent) April 23, 2020
National security spokesperson to continue pressing for a temporary ceasefire that Washington wants to last for at least six weeks
mena2 hours ago
It was RCB's third win — and second in a row — in 10 matches so far this season, keeping their slim hopes of reaching the playoffs alive
cricket2 hours ago
Offshoring business operations to captive centres has proven to be a cost-effective and efficient strategy
realty2 hours ago
Tourism minister Ahmed Al Khateeb says all the kingdom's projects are far away from the conflict
mena2 hours ago
A wave of exceptionally hot weather has blasted the region over the past week, sending the mercury as high as 45 degrees Celsius
asia2 hours ago
This was following a Reuters report that some senior US officials did not find Israel's assurances credible
world2 hours ago
Chinese Premier Li Qiang promises to Musk that the country will always be open to foreign firms
auto2 hours ago
Prevailing market trends, investment opportunities and growth strategies instilling confidence in stakeholders navigating Dubai's dynamic landscape
realty2 hours ago